Stock Events

Stock Events

Co-Diagnostics

€0

105

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

14MayExpected

Next

-3.19

-2.86

-2.53

-2.19

Expected EPS

-3.1949625

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C970.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

QIAGEN offers diagnostic solutions, including molecular diagnostics which directly compete with Co-Diagnostics' testing technologies.

Thermo Fisher Scientific

Thermo Fisher Scientific provides a broad range of diagnostic and research products, including molecular diagnostics that compete with CODX offerings.

Bio-Rad Laboratories

Bio-Rad Laboratories offers a variety of diagnostic tests and systems, including PCR-based tests, which are in direct competition with Co-Diagnostics' products.

Quest Diagnostics

Quest Diagnostics provides diagnostic testing services, including molecular diagnostics, competing with Co-Diagnostics in the laboratory testing market.

Laboratory Corporation of America offers a wide range of diagnostic tests, including molecular diagnostics, making it a competitor in the diagnostics market.

Abbott Laboratories

Abbott Laboratories offers a broad portfolio of diagnostic products, including molecular diagnostics, competing across several of Co-Diagnostics' market segments.

Agilent Technologies

Agilent Technologies provides life sciences, diagnostics, and applied chemical markets with instruments and services, including diagnostics that compete with Co-Diagnostics.

Baxter International

Baxter International offers a range of medical devices and laboratory equipment, some of which are used in diagnostic applications that compete with Co-Diagnostics.

Roche Holding AG is a major player in diagnostics and pharmaceuticals, including molecular diagnostics, making it a significant competitor to Co-Diagnostics in the global diagnostics market.

About

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Show more...

CEO

Mr. Dwight H. Egan

Employees

115

Country

United Kingdom

ISIN

US1897632048

Listings

0 Comments

Share your thoughts

FAQ

What is Co-Diagnostics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Co-Diagnostics stocks are traded under the ticker C970.STU.

When is the next Co-Diagnostics earnings date?▼

Co-Diagnostics is going to release the next earnings report on May 14, 2026.

How many employees does Co-Diagnostics have?▼

As of May 13, 2026, the company has 115 employees.

In which sector is Co-Diagnostics located?▼

Co-Diagnostics operates in the Other sector.

When did Co-Diagnostics complete a stock split?▼

The last stock split for Co-Diagnostics was on January 02, 2026 with a ratio of 1:30.

Where is Co-Diagnostics headquartered?▼

Co-Diagnostics is headquartered in Salt Lake City, United Kingdom.